14,016 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Acquired by OZ Management LP

OZ Management LP bought a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 14,016 shares of the company’s stock, valued at approximately $450,000.

Other large investors also recently modified their holdings of the company. Cribstone Capital Management LLC increased its position in Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock worth $101,000 after buying an additional 100 shares during the period. Bronfman E.L. Rothschild L.P. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after buying an additional 261 shares in the last quarter. Financial Architects Inc boosted its stake in shares of Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock worth $143,000 after buying an additional 100 shares in the last quarter. Botty Investors LLC purchased a new stake in shares of Teva Pharmaceutical Industries Limited during the first quarter worth approximately $160,000. Finally, Advisory Services Network LLC bought a new stake in Teva Pharmaceutical Industries Limited during the first quarter worth about $163,000. 56.26% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Limited (TEVA) traded up 0.38% during trading on Tuesday, hitting $31.95. The stock had a trading volume of 5,314,284 shares. Teva Pharmaceutical Industries Limited has a 52-week low of $27.59 and a 52-week high of $55.79. The stock’s 50-day moving average is $31.09 and its 200-day moving average is $32.49. The stock has a market capitalization of $32.46 billion, a PE ratio of 409.62 and a beta of 0.46.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, May 11th. The company reported $1.06 EPS for the quarter, hitting the consensus estimate of $1.06. The firm had revenue of $5.63 billion for the quarter, compared to analyst estimates of $5.69 billion. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 17.0% compared to the same quarter last year. During the same period last year, the company earned $1.20 earnings per share. On average, analysts predict that Teva Pharmaceutical Industries Limited will post $4.75 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 22nd. Shareholders of record on Monday, June 5th were issued a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 4.26%. The ex-dividend date was Thursday, June 1st. Teva Pharmaceutical Industries Limited’s payout ratio is currently 5,802.90%.

ILLEGAL ACTIVITY NOTICE: This article was reported by BBNS and is the sole property of of BBNS. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://baseballnewssource.com/markets/oz-management-lp-acquires-new-stake-in-teva-pharmaceutical-industries-limited-teva-updated-updated-updated/1072793.html.

Several analysts have weighed in on the stock. Vetr cut shares of Teva Pharmaceutical Industries Limited from a “strong-buy” rating to a “buy” rating and set a $31.94 price objective for the company. in a research note on Monday, May 22nd. Jefferies Group LLC reissued a “hold” rating and issued a $33.00 target price on shares of Teva Pharmaceutical Industries Limited in a report on Friday, June 23rd. CIBC reaffirmed a “buy” rating and set a $43.00 price target on shares of Teva Pharmaceutical Industries Limited in a report on Friday, April 7th. Oppenheimer Holdings, Inc. set a $43.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a report on Thursday, April 6th. Finally, Zacks Investment Research raised shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a report on Monday, April 17th. Sixteen research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $42.78.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana
Mike Trout Returns from Injury With Single and Stole Base
Mike Trout Returns from Injury With Single and Stole Base
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana
Players Know They Could Go From All-Star Game to Trade Block
Players Know They Could Go From All-Star Game to Trade Block


Leave a Reply

 
© 2006-2017 BBNS.